Charles Schwab
INBX icon

Charles Schwab’s Inhibrx INBX Stock Holding History

Charles Schwab’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72M Buy
28,678
+3,007
+12% +$301K ﹤0.01% 2682
2026
Q1 		$1.73M Sell
25,671
-1,670
-6% -$124K ﹤0.01% 2752
2025
Q4 		$2.16M Sell
27,341
-452
-2% -$30.8K ﹤0.01% 2740
2025
Q3 		$936K Hold
27,793
– – ﹤0.01% 2973
2025
Q2 		$397K Sell
27,793
-4,864
-15% -$62.9K ﹤0.01% 3212
2025
Q1 		$457K Hold
32,657
– – ﹤0.01% 3111
2024
Q4 		$503K Hold
32,657
– – ﹤0.01% 3138
2024
Q3 		$511K Buy
32,657
+5,885
+22% +$82.7K ﹤0.01% 3154
2024
Q2 		$379K Buy
+26,772
New +$418K ﹤0.01% 3300

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's INBX Position: Q2 2026 in Review

Charles Schwab increased its Inhibrx (INBX) stake by 12% in Q2 2026, buying an estimated $301K and bringing the position to 28,678 shares worth $2.72M. The position accounts for ﹤0.01% of the portfolio, ranked #2682.

Charles Schwab first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Charles Schwab held 28,678 shares of Inhibrx worth $2.72M as of Q2 2026.
  • Charles Schwab bought 3,007 Inhibrx shares in Q2 2026, an estimated $301K.
  • Inhibrx made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2682 holding.
  • Charles Schwab first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.